Juniper and Crystec sign agreement for next-generation medicines

Both companies will collaborate as part of this UK-based consortium of partners that includes two of the world’s biggest pharmaceutical companies. The programme aims to develop and demonstrate the capability of supercritical fluid technology in manufacturing smarter, higher quality pharmaceutical products, whilst moving products more quickly from research to the marketplace.

In just 3 years, AMSCI is expecting the joint platform to create products from concept to manufacture.

CrystecPharma designs crystals and particles aimed at meeting targeted performance requirements of a medicine. Juniper Pharma Services will bring its expertise in characterisation, formulation development and GMP production to the supercritical fluid manufacturing platform.

Dr Nikin Patel, president at Juniper Pharma Services, said: “Working with CrystecPharma in collaboration with the other AMSCI partners is very exciting, as this alliance will produce a real step change in the advanced manufacturing of next-generation medicines.”

As a result of the project, CrystecPharma will refocus its manufacturing capability from China to the UK, working with Juniper Pharma Services as its international contract development and manufacturing organisation (CDMO) partner. The technology company aims to develop three new products through this programme.

Paul Thorning, CEO at CrystecPharma, said: “Such a collaborative campaign has the potential to really demonstrate the global competitiveness of the UK in pharmaceutical technology development and manufacturing.

“It will benefit from the invaluable expertise of the team at Juniper, which will enable our novel technology to move into a GMP compliant environment. Working closely with Juniper in this way allows us to rapidly establish the manufacturing capabilities needed to see us through to clinical trials.”

With an established track record of helping pharmaceutical companies and emerging biotechs to creatively develop new products and platforms, Juniper Pharma Services is able to mitigate risk and optimise formulation performance through its science-led approach to projects.

This is the latest major project for the CDMO after it entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles.